Drug Targets

Research discussing potential therapeutic coronavirus targets

Published and Preprint Papers

Title

Altmetric

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

The SARS-CoV-2 main protease M pro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells.

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination.

The Global Phosphorylation Landscape of SARS-CoV-2 Infection.

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.

Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort.

A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19.

Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis.